NYSE:CRWV.O 14 February 2026

March 27, 2026, 7:54 PM EDT. Pacific Biosciences of California (PACB) shares fell 6.67% to $1.26, underperforming the S&P 500's 1.67% decline. The stock has lost 24.16% over the past month, trailing the Medical sector's 7.36% drop. Analysts expect earnings per share to fall 13.33% year-over-year to -$0.17, while revenue is projected to rise 10.36% to $41 million for the quarter. Full-year estimates forecast EPS of -$0.54 and revenue of $175.4 million. Despite recent declines, PACB holds a strong Zacks Rank #1 (Strong Buy), reflecting analyst optimism. The Medical - Instruments industry ranks in the top 39% by Zacks Industry Rank, indicating sector strength. Investors will watch upcoming earnings closely for clearer direction.